Showcase

公司名稱 Company Name

祥根生物(香港)有限公司
Sungening Biological (Hong Kong) Co., Limited

公司網站 Company Website 

公司簡介 Company Background
祥根生物聚焦環肽藥物創新研發,擁有自主環肽藥物研發平台。布局多款 Best-in-Class 核心管線,抗真菌藥物SG1001中國臨床II期、美國臨床I期推進中,口服降脂環肽藥物SG6001即將申報 IND。祥根研發覆蓋抗真菌、高血脂等重大臨床需求,致力打造全球環肽藥物創新標桿。
Sungening specializes in the innovative R&D of cyclic peptide drugs, with its headquarters in Shenzhen. Its Hong Kong subsidiary enables cross-border collaborative R&D, housing a cyclic peptide screening platform and clinical headquarters. We have built the SunCyclix™ cyclic peptide R&D system, empowered by mRNA display technology, AI-aided screening and medicinal chemistry optimization. Sungening boasts a portfolio of Best-in-Class core pipelines: SG1001 (antifungal) is in Phase II clinical trial in China and Phase I in the US; SG6001 (oral lipid-lowering cyclic peptide) is pending IND filing. Covering major clinical needs including antifungal and hyperlipidemia, Sungening aspires to be a global benchmark for cyclic peptide drug innovation.
陳列產品之簡介 Description of displayed product
SG1001(BIC,II期臨床):侵襲性曲黴病(免疫功能低下患者群體中死亡率超 50% 的真菌病);全球僅兩款處於臨床階段的二氫乳清酸脫氫酶抑制劑;安全性優於兩性黴素 B,可解決伏立康唑等唑類藥物的耐藥性難題;該藥大中華區權益已與麗珠醫藥達成超 1400 萬美元授權合作,開放海外權益。
-SG1001 (Best-in-Class, Phase 2 processing):• Indication: Invasive Aspergillosis (50+% death rate fungal diseases in immunocompromised patients);• Position: The only 2 DHODHi in the clinical stage. Better safety than Amphotericin-B, addressing risks of azole resistance (e.g., to voriconazole) ;• SG1001 already secured a $14M+ deal for Greater China rights with Livzon, and now offer exclusive overseas out-licensing rights.-SG6001 (Differentiated Oral PCSK9 Inhibitor, IND submission in Q4 2026)• Indication: Hyperlipidemia (High LDL-C)• Position: World’ s 3rd oral PCSK9i after MK-0616 (Merck, Phase 3) and AZD0780 (AZ, Phase 3). Animal Model (hamster & rhesus monkey models) proves superior LDL-C lowering efficacy vs. MK-0616.• SG6001 offer global out-licensing or co-development rights.
公司產品 Company products